A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 11, 2015, Pages 1298-1305

  Dulhunty, Joel M ^a,b,g   Roberts, Jason A ^a,b,o   Davis, Joshua S ^c,d   Webb, Steven A R ^e,f,k,al   Bellomo, Rinaldo ^g,h   Gomersall, Charles ^i,j,ak   Shirwadkar, Charudatt ^a,k   Eastwood, Glenn M ^g,aj   Myburgh, John ^a,l,m,y   Paterson, David L ^a,b,n   Starr, Therese ^a,b,o   Paul, Sanjoy K ^o   Lipman, Jeffrey ^a,b   Peck, Leah ^g   Young, Helen ^g   Boschert, Catherine ^p   Fletcher, Jason ^p   Smith, Julie ^p   Nand, Kiran ^k   Smith, Judy ^ab   Harney, Amy ^q   Rodgers, Helen ^q   Van Haren, Frank ^q   Clarke, Sally ^r   Durham, David ^r   Hannan, Catherine ^r   Matheson, Elisha ^r   Schwartz, Kate ^r   Thomas, Karen ^r   Bone, Allison ^s   Cattigan, Claire ^s   Elderkin, Tania ^s   Salerno, Tania ^s   Cameron, Robert ^t   Ellis, Katrina ^t   Hatter, Sheridan ^t   Sanap, Milind ^u   Soar, Natalie ^u   Wood, Josette ^u   Chan, Karen ^v   Heffernan, Aaron ^v   Lai, Nai An ^v   Moss, Catherine ^v   Sheehy, Kate ^v   Duroux, Maree ^w   Ratcliffe, Megan ^w   Shone, Samantha ^w   Warhurst, Timothy ^w   Dunlop, Rachel ^b   Stuart, Janine ^b   Udy, Andrew ^b   Cooper, David ^x   McAllister, Rick ^x   Cheng, Andrew ^y   Inskip, Deborah ^y   Miller, Jennene ^y   Knowles, Serena ^z   Reynolds, Claire ^z   Rudham, Sam ^z   Baker, Stuart ^aa   Hepburn, Kristy ^aa   Roberts, Brigit ^aa   Woods, Paul ^aa   Chatterjee, Indranil ^ab   Cullen, Martin ^ac   Kong, Jing ^ac   Nayyar, Vineet ^ac   Whitehead, Christina ^ac   Leung, Patricia ⁱ   Gilder, Eileen ^ad   McCarthy, Lianne ^ad   McGuiness, Shay ^ad   Parke, Rachael ^ad   Benefield, Kirsten ^ad   Chen, Yan ^ad   McArthur, Colin ^ad   Newby, Lynette ^ad   Henderson, Seton ^ae   Mehrtens, Jan ^ae   Noble, Sascha ^ae   Chadwick, Lesley ^af   Freebain, Ross ^af   Hogan, Chantal ^ag   Kazemi, Alex ^ag   Rust, Laura ^ag   Song, Rima ^ag   Tilsley, Anna ^ag   Williams, Anthony ^ag   Andrews, Lynn ^ah   Dinsdale, Richard ^ah   Hunt, Anna ^ah   Hurford, Sally ^ah   Mackle, Diane ^ah   Ongley, Jessica ^ah   Young, Paul ^ah   Durning, John ^ai   Frengley, Robert ^ai   La Pine, Mary ^ai   McCracken, Geoff ^ai   Sharma, Swarna Baskar ^ai   Kollef, Marin ^e   Turnidge, John ^am   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g AUSTIN HOSPITAL   (Australia)

^h MONASH UNIVERSITY   (Australia)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^k BLACKTOWN HOSPITAL   (Australia)

^l GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^m UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁿ UNIVERSITY OF QUEENSLAND   (Australia)

^o QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^p Bendigo Hospital   (Australia)

^q CANBERRA HOSPITAL   (Australia)

^r FLINDERS MEDICAL CENTRE   (Australia)

^s GEELONG HOSPITAL   (Australia)

^t GOSFORD HOSPITAL   (Australia)

^u LYELL MCEWIN HOSPITAL   (Australia)

^v Metro South Health   (Australia)

^w REDCLIFFE HOSPITAL   (Australia)

^x ROYAL HOBART HOSPITAL   (Australia)

^y ST GEORGE HOSPITAL   (Australia)

^z ST VINCENT S HOSPITAL   (Australia)

^aa SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^ab TOOWOOMBA HOSPITAL   (Australia)

^ac WESTMEAD HOSPITAL   (Australia)

^ad AUCKLAND CITY HOSPITAL   (New Zealand)

^ae CHRISTCHURCH HOSPITAL   (New Zealand)

^af HAWKE S BAY HOSPITAL   (New Zealand)

^ag MIDDLEMORE HOSPITAL   (New Zealand)

^ah WELLINGTON HOSPITAL   (New Zealand)

^ai WAIKATO HOSPITAL   (New Zealand)

^aj PRINCE OF WALES HOSPITAL   (Australia)

^ak UNIVERSITY OF NEW SOUTH WALES   (Australia)

^al BARNES JEWISH HOSPITAL   (United States)

^am UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

Antibiotic; Clinical outcome; Intensive care; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA LACTAM ANTIBIOTIC; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ADULT; AGED; APACHE; ARTICLE; BACTEREMIA; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; HAZARD RATIO; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84946231220     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201505-0857OC     Document Type: Article

References (30)

1. Dulhunty JM, Paterson D, Webb SA, Lipman J. Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. Anaesth Intensive Care 2011;39:231-237.
2. Corona A, Bertolini G, Lipman J, Wilson AP, Singer M. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010;65: 1276-1285.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10, quiz 11-12.
4. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat Rev Microbiol 2004;2:289-300.
5. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007;13:598-606.
6. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, et al.; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current b-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014;58:1072-1083.
7. Buyle FM, Decruyenaere J, De Waele J, Tulkens PM, Van Audenrode T, Depuydt P, Claeys G, Robays H, Vogelaers D. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis 2013;32:763-768.
8. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25:62-67.
9. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of b-lactams. Crit Care 2011;15: R206.
10. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142-150.
11. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration? Crit Care Med 2009;37:926-933.
12. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J, et al. Risk factors for target non-attainment during empirical treatment with b-lactam antibiotics in critically ill patients. Intensive Care Med 2014;40:1340-1351.
13. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-936.
14. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-363.
15. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009;33:464-468.
16. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013;56:272-282.
17. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-291.
18. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013;56:236-244.
19. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005;5:581-589.
20. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of betalactam antibiotics. Crit Care Med 2009;37:2071-2078.
21. Shiu J, Wang E, Tejani AM, Wasdell M. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 2013;3: CD008481.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
23. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, et al.; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australasian Society for Infectious Diseases Clinical Research Network. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resusc 2013;15: 179-185.
24. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332-339.
25. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012;16: R113.
26. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutic initial b-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012;142:30-39.
27. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis 2006;56:57-62.
28. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40: 219-223.
29. Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Pearson JC, Bell JM; Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance Community-onset Gram-negative Surveillance Program annual report, 2010. Commun Dis Intell Q Rep 2013;37: E219-E223.
30. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, et al.; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014;14:498-509.